PIMAVANSERIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Pimavanserin, and when can generic versions of Pimavanserin launch?
Pimavanserin is a drug marketed by MSN and Zydus and is included in three NDAs.
The generic ingredient in PIMAVANSERIN is pimavanserin tartrate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pimavanserin tartrate profile page.
Summary for PIMAVANSERIN
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 3 |
| Clinical Trials: | 37 |
| DailyMed Link: | PIMAVANSERIN at DailyMed |
Recent Clinical Trials for PIMAVANSERIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Ohio State University | Phase 2 |
| State University of New York - Downstate Medical Center | Early Phase 1 |
| ACADIA Pharmaceuticals Inc. | Early Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for PIMAVANSERIN
US Patents and Regulatory Information for PIMAVANSERIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msn | PIMAVANSERIN | pimavanserin tartrate | CAPSULE;ORAL | 214925-001 | Jan 16, 2024 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Zydus | PIMAVANSERIN | pimavanserin tartrate | CAPSULE;ORAL | 214493-001 | Jan 16, 2024 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Zydus | PIMAVANSERIN | pimavanserin tartrate | TABLET;ORAL | 214502-001 | Jan 16, 2024 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
